Phase I expansion study of cabozantinib plus nivolumab (CaboNivo) in metastatic urothelial carcinoma (mUC) patients (pts) with progressive disease following immune checkpoint inhibitor (ICI) therapy.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.5037
Abstract: 5037Background: Previous treatment with ICI is more common in clinical practice since recent FDA-approval of 5 ICIs in second-line and 2 in first-line for mUC. There is lack of data regarding the u... read more here.
Keywords: cabozantinib plus; plus nivolumab; nivolumab cabonivo; study cabozantinib ... See more keywords
A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.6010
Abstract: 6010Background: The efficacy of treatment for recurrent endometrial cancer (EC) remains limited. Vascular endothelial growth factor and inflammatory chemokines are proangiogenic factors and immune ... read more here.
Keywords: study cabozantinib; recurrent endometrial; randomized phase; endometrial cancer ... See more keywords